ArticleHaematologica2026
Novel cryptic ADAMTS13 epitopes uncover a distinct open ADAMTS13 conformation in immune-mediated TTP.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Open ADAMTS13 conformation is gaining clinical interest as a biomarker for diagnosing immune-mediated thrombotic thrombocytopenic purpura (iTTP) and monitoring patients in remission for increased risk of relapse. Nevertheless, little is known about how open the structure of ADAMTS13 is exactly in iTTP patients. In this study, we aimed to assess the uniformity of open ADAMTS13 across iTTP patients. To do this, we identified four monoclonal antibodies that recognize epitopes that are cryptic in closed ADAMTS13 from healthy donors but accessible upon antibody-mediated ADAMTS13 opening. Distributed across the D, T7, T8 and CUB1 domains, these cryptic epitopes indicate ADAMTS13 closure through multiple interdomain contacts extending beyond the well-described S-CUB interaction. Interestingly, all acute iTTP patients consistently present one distinct open ADAMTS13 in which all novel cryptic epitopes are accessible. During remission, closed ADAMTS13 with all epitopes being cryptic is predominantly found in patients with restored activity, whereas distinct open ADAMTS13 is present in patients with subclinical disease. Furthermore, IgG from iTTP patients opened the conformation of ADAMTS13, corroborating the role of pathogenic autoantibodies in opening ADAMTS13 in iTTP. These new cryptic epitope-recognizing monoclonal antibodies hold promise to further enhance our understanding of compactly closed conformation of ADAMTS13 and may support the prediction of early relapses in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.